Clinical Trial Detail

NCT ID NCT03331198
Title Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Juno Therapeutics, a Subsidiary of Celgene
Indications

chronic lymphocytic leukemia

CLL/SLL

Therapies

JCAR017

Ibrutinib + JCAR017

Age Groups: senior adult

No variant requirements are available.